Announcements Trials
Browse Landscape

Phase

Phase 1 14Phase 2 3

Status

Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Genitourinary 1

Conditions

Neoplasms 3Pancreatic Neoplasms 1Neoplasm Metastasis 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × budigalimab × Clear all
NCT06119217 2026-05-13

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

Trishula Therapeutics, Inc.

Phase 2 Completed
194 enrolled 16 charts
Gastrointestinal

Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT05822752 2025-08-14

LIVIGNO-1

AbbVie

Phase 2 Active not recruiting
130 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT06632951 2025-08-11

LIVIGNO-3

AbbVie

Phase 2 Active not recruiting
150 enrolled
Genitourinary

Carcinoma, Transitional Cell, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡